Metraipolis › archive › dc_7d9958cc1098
PET/CT guided tuberculosis treatment shortening: a randomized trial — Europe PMC PPR:PPR920115
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR920115
- DOI
- 10.1101/2024.10.03.24314723
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T15:18:53.137Z
- SHA-256 of the archived text
efa3f40a268a94bac98fea0e9b1de5af4e91360a0da8ac181c63ed149a34b730- Stable URL of this page
https://metraipolis.com/documento/dc_7d9958cc1098
How to cite
PET/CT guided tuberculosis treatment shortening: a randomized trial — Europe PMC PPR:PPR920115 — Europe PMC, https://europepmc.org/article/PPR/PPR920115 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7d9958cc1098 (Metraipolis archive dc_7d9958cc1098, sha256 efa3f40a268a94bac98fea0e9b1de5af4e91360a0da8ac181c63ed149a34b730)
BibTeX
@misc{dc7d9958cc1098,
title = {PET/CT guided tuberculosis treatment shortening: a randomized trial — Europe PMC PPR:PPR920115},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR920115},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7d9958cc1098; sha256 efa3f40a268a94bac98fea0e9b1de5af4e91360a0da8ac181c63ed149a34b730},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR920115. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Six months of chemotherapy using current agents is standard of care for pulmonary, drug-sensitive tuberculosis (TB), even though some are believed to be cured more rapidly and others require longer therapy. Understanding what factors determine the length of treatment required for durable cure in individual patients would allow individualization of treatment durations, provide better clinical tools to determine the of appropriate duration of new regimens, as well as reduce the cost of large Phase III studies to determine the optimal combinations to use in TB control programs. We conducted a randomized clinical trial in South Africa and China that recruited 704 participants with newly diagnosed, drug-sensitive pulmonary tuberculosis and stratified them based on radiographic disease characteristics as assessed by FDG PET/CT scan readers. Participants with less extensive disease (N=273) were randomly assigned to complete therapy after four months or continue receiving treatment for six months. Amongst participants who received four months of therapy, 17 of 141 (12.1%) experienced unfavorable outcomes compared to only 2 of 132 (1.5%) who completed six months of treatment (treatment success 98.4% in B, 86.7% in C (difference -11.7%, 95% CI, -18.2%, -5.3%)). In the non-randomized arm that included participants with more extensive disease, only 8 of 248 (3.2%) experienced unfavorable outcomes. Total cavity volume and total lesion glycolysis at week 16 were significantly associated with risk of unfavorable outcome in the randomized participants. Based on PET/CT scans at TB recurrence, bacteriological relapses (confirmed by whole genome sequencing) predominantly occurred in the same active cavities originally present at baseline. Automated segmentation of the serial PET/CT scans was later performed, and machine-learning was used to classify participants according to their likelihood of relapse, allowing the development of predictive models with good performance based on CT, PET, microbiological and clinical characteristics. These results open the possibility for more efficient studies of future TB treatment regimens. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: medRxiv, 2024 (prima pubblicazione 2024-10-04). Identificativi: DOI 10.1101/2024.10.03.24314723. Pagina: https://europepmc.org/article/PPR/PPR920115 — https://doi.org/10.1101/2024.10.03.24314723. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T15:11:56.353Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.